Tresiba Cost in Missouri 2026: What You'll Actually Pay

What Is the List Price of Tresiba in Missouri?

Novo Nordisk sets the wholesale acquisition cost for Tresiba at approximately $510 per month for a standard supply in 2026. Almost nobody pays that figure. Pharmacy benefit managers negotiate rebates, discount programs slash the cash price to around $35 per month at Missouri retail chains, and manufacturer copay assistance covers commercially insured patients. The $510 number matters mainly as a ceiling when calculating out-of-pocket costs during insurance deductible periods.

Tresiba is a long-acting basal insulin with a duration of action exceeding 42 hours, which underpins its once-daily dosing schedule [1]. The FDA approved Tresiba in September 2015 for adults with type 1 and type 2 diabetes, and the label was later extended to pediatric patients aged 1 year and older [2]. Its ultra-long half-life produces a flatter, more predictable pharmacokinetic profile compared with insulin glargine U-100, which matters clinically when patients miss or shift doses.

The DEVOTE cardiovascular outcomes trial (N=7,637) compared insulin degludec with insulin glargine U-100 in high-cardiovascular-risk type 2 diabetes patients over a median 2-year follow-up. The primary endpoint, major adverse cardiovascular events (MACE), occurred in 8.5% of the degludec group versus 9.3% of the glargine group, confirming non-inferiority (P<0.001 for non-inferiority) [3]. Severe hypoglycemia rates were 40% lower with degludec (P<0.001) [3]. That hypoglycemia advantage carries a real cost-of-care implication: fewer emergency visits.

How Much Do Missouri Residents Pay at the Pharmacy?

Cash price after discount programs is approximately $35 per month. The Novo Nordisk manufacturer list price of $510 per month applies only when no coverage or discount program is active.

Missouri retail pharmacies, including Walgreens, CVS, Walmart Pharmacy, and Price Chopper, all participate in third-party discount networks such as GoodRx, RxSaver, and NeedyMeds [4]. Presenting a free GoodRx coupon at the pharmacy counter typically brings a 3-mL FlexTouch pen (100 units/mL) down to the $30, $40 range. Prices vary by ZIP code; rural Missouri pharmacies sometimes show slightly higher cash prices than Kansas City or St. Louis metro locations, so checking multiple coupon platforms before filling is worth a few minutes.

The American Diabetes Association's 2024 Standards of Care note that insulin affordability remains a top barrier to adherence, with cost-related underuse affecting an estimated 1.3 million Americans annually [5]. Missouri residents are not exempt from that pattern. A 2022 analysis in JAMA Internal Medicine found that patients who rationed insulin were 3.4 times more likely to experience a diabetes-related emergency department visit compared with those who took their prescribed doses consistently [6].

Biosimilar insulins have compressed brand-name list prices since 2023. Rezvoglar (insulin glargine-aglr, Eli Lilly) launched at 78% below Lantus list price, and Civica Rx's cimerli followed [7]. These are glargine biosimilars, not degludec, but their market entry has indirectly pressured Novo Nordisk to expand its own savings programs.

Does Missouri Medicaid Cover Tresiba?

Missouri Medicaid (MO HealthNet) covers Tresiba for type 1 diabetes. For type 2 diabetes, Tresiba is not on the preferred drug list as of 2026, meaning it requires prior authorization and is frequently denied in favor of lower-cost basal insulins such as NPH or glargine biosimilars.

MO HealthNet's pharmacy benefit follows the Preferred Drug List (PDL) administered by Magellan Rx Management. The preferred basal insulins for type 2 diabetes on the Missouri PDL are insulin glargine products (including biosimilar versions) and NPH insulin [8]. Tresiba sits in a non-preferred tier, requiring documentation that preferred agents caused unacceptable hypoglycemia or that clinical circumstances make once-daily flexibility medically necessary.

For type 1 diabetes, MO HealthNet recognizes that basal insulin selection is more individualized, and Tresiba is covered with prescriber attestation of medical necessity. Patients with recurrent severe hypoglycemia on glargine, documented dawn phenomenon, or variable shift-work schedules that make a fixed injection time difficult stand the best chance of prior authorization approval.

The prior authorization process in Missouri typically takes 3, 5 business days. An expedited review can be requested when a patient faces imminent clinical risk. Physicians should document: current A1c, history of hypoglycemic episodes with dates and severity, prior insulin regimens tried, and the specific clinical rationale for Tresiba over preferred alternatives. The ADA's 2024 Standards of Care (Section 9) explicitly recommend individualized basal insulin selection based on hypoglycemia risk, adherence patterns, and cost [5].

Is Compounded Insulin Degludec Legal in Missouri?

Compounded insulin degludec is available through state-licensed 503A compounding pharmacies in Missouri. Federal law permits 503A pharmacies to compound patient-specific preparations, including insulin analogs, when a valid prescriber-patient relationship exists and the preparation is not commercially available in the required form or strength.

Missouri follows the federal 503A framework established under the Drug Quality and Security Act of 2013 [9]. A 503A pharmacy compounds in response to individual prescriptions; it does not produce commercial-scale batches. The Missouri Board of Pharmacy licenses and inspects these facilities. Patients should verify that any pharmacy compounding insulin degludec holds an active Missouri Board of Pharmacy license, which is searchable at the board's public portal.

Pricing for compounded insulin degludec at Missouri 503A pharmacies varies considerably. Some HealthRX-affiliated compounding partners have offered basal insulin degludec preparations at significantly reduced cost compared to the brand Tresiba, though the preparation's purity, concentration, and sterility standards depend entirely on the specific pharmacy's quality controls. The FDA does not approve compounded preparations, meaning bioequivalence to Tresiba has not been independently verified for any specific compounded version [10].

A clinically reasonable approach for Missouri prescribers: reserve brand Tresiba for patients with commercial insurance that covers it at a low tier, use the Novo Nordisk savings card for commercially insured patients paying cash, and discuss compounded degludec only with patients who are uninsured or underinsured after confirming the compounding pharmacy's inspection history. The FDA's guidance on compounded drug products notes that "patients who receive compounded drugs may face higher risks than patients who take FDA-approved drugs" [10], a consideration that belongs in the shared decision-making conversation.

Which Insurance Plans Cover Tresiba in Missouri?

Most large commercial plans available through Missouri's federally facilitated marketplace cover Tresiba, though tier placement and prior authorization requirements differ substantially by plan and formulary year.

Blue Cross Blue Shield of Missouri, Cigna, Aetna, and UnitedHealthcare all sell ACA marketplace plans in Missouri. Tresiba's formulary tier ranges from Tier 2 (preferred brand) to Tier 3 (non-preferred brand) depending on the plan. A Tier 3 placement typically means 30 to 50% coinsurance during the deductible phase, which can approach $150, $200 per month before the deductible is met. After the deductible, copays on Tier 3 plans usually fall to $40, $75 per 30-day supply.

Employer-sponsored plans in Missouri often mirror these tiers. The best way to confirm coverage before filling is to call the pharmacy benefits number on the insurance card and ask specifically: "What tier is insulin degludec (Tresiba) on my current formulary, and does it require prior authorization?" That question takes about four minutes and prevents a $400 surprise at the counter.

Medicare Part D plans in Missouri that include Tresiba typically place it on Tier 3 or Tier 4. The Inflation Reduction Act capped Medicare Part D out-of-pocket insulin costs at $35 per month per covered insulin beginning January 2023 [11]. That cap applies only to insulins on the plan's formulary; if Tresiba is excluded, the cap does not apply. Patients on Medicare should use Medicare's Plan Finder tool to compare formularies during open enrollment.

The American Association of Clinical Endocrinology (AACE) 2023 Diabetes Management Algorithm recommends long-acting basal insulin analogs with low hypoglycemia risk as first-line basal therapy for most patients, noting that "cost and access should be explicitly discussed at every prescribing encounter" [12]. That guideline language supports appeals when insurers deny Tresiba in favor of a cheaper agent that previously caused symptomatic hypoglycemia.

How the Novo Nordisk Savings Card Works in Missouri

The Novo Nordisk Patient Assistance Program and Nordisk Together savings card can reduce Tresiba costs to $0, $99 per month for eligible commercially insured Missouri patients. Uninsured patients with incomes below 400% of the federal poverty level may qualify for free insulin through the Patient Assistance Program.

The savings card is available at NovoNordisk-US.com and at most Missouri retail pharmacies. Eligibility requires: a valid Tresiba prescription, commercial insurance (Medicare and Medicaid patients are ineligible for the card itself), and income documentation for the free-drug program tier. The card works as a secondary payer at the pharmacy counter; it covers the gap between what insurance pays and the patient's copay, up to the program maximum.

For 2026, the standard savings card reduces the commercially insured patient's cost to no more than $99 per 30-day supply. Patients with high-deductible health plans who are paying out-of-pocket before the deductible is met qualify for a separate $0 copay offer, subject to a monthly supply cap. Terms change annually; patients should re-enroll or re-verify eligibility each January.

Insulin Together, Novo Nordisk's free-insulin program, provides Tresiba at no cost to uninsured or underinsured patients who meet income criteria. The application process requires a physician signature, proof of income, and a completed enrollment form. Approval typically takes 2 to 4 weeks, so planning ahead matters for patients transitioning off insurance coverage.

The STEP-2 trial, while focused on semaglutide rather than insulin, is relevant context here: it demonstrated that GLP-1 receptor agonist therapy in type 2 diabetes reduced the need for basal insulin dose escalation, with semaglutide 2.4 mg producing 9.6% mean weight loss at 68 weeks versus 3.4% for placebo, with a corresponding reduction in insulin requirements [13]. Missouri patients on Tresiba who also qualify for GLP-1 therapy may reduce their insulin dose over time, indirectly reducing cost.

Telehealth Prescribing of Tresiba in Missouri

Tresiba can be prescribed via telehealth in Missouri. A valid prescriber-patient relationship, including a synchronous audio-video visit, satisfies Missouri's prescribing standards for insulin. Missouri does not require an in-person visit for initial insulin prescribing as of 2026.

Missouri's telehealth law (Mo. Rev. Stat. Section 191.1145) permits prescribing via two-way real-time audio-visual communication when the standard of care is met [14]. Insulin is not a controlled substance under the Controlled Substances Act, so the DEA's in-person prescribing rule for Schedule II, III drugs does not apply. A board-certified endocrinologist or primary care physician licensed in Missouri can initiate Tresiba during a telehealth encounter, send the prescription electronically to any Missouri retail or mail-order pharmacy, and complete follow-up labs remotely.

HealthRX telehealth visits for diabetes management include A1c review, hypoglycemia risk assessment, and titration protocol setup, all within a single 30-minute video appointment. Patients who have been rationing insulin due to cost are triaged to the savings card and patient assistance options discussed above before the first prescription is sent.

For patients starting Tresiba, the FDA-approved label recommends initiating at 10 units once daily (or converting from another basal insulin on a unit-to-unit basis) and titrating every 3 to 4 days to achieve fasting glucose targets [2]. Remote glucose data via connected glucometers or continuous glucose monitors (CGMs) can support telehealth titration safely. A 2021 randomized trial published in Diabetes Care (N=241) found that telehealth-guided insulin titration achieved A1c reduction of 1.4% at 24 weeks, non-inferior to in-person titration (P<0.001 for non-inferiority) [15].

Titration, Dosing, and Clinical Context

Insulin degludec's pharmacology makes it forgiving of dose-timing variability. The prescriber's primary job is selecting the right starting dose and setting realistic titration targets.

The FDA label for Tresiba specifies a starting dose of 10 units once daily for insulin-naive type 2 diabetes patients [2]. For type 1 diabetes, total daily insulin dose is calculated at approximately 0.5 units/kg/day, with roughly half allocated to basal and half to prandial coverage. Titration follows a fasting glucose target, typically 80 to 130 mg/dL per ADA 2024 Standards [5], by increasing the dose by 2 units every 3 days when fasting glucose exceeds the target on 3 consecutive days.

The SWITCH 1 and SWITCH 2 trials (crossover design, N=501 and N=721 respectively) compared insulin degludec with insulin glargine U-100 in type 1 and type 2 diabetes. In SWITCH 1 (type 1), the confirmed hypoglycemia rate was 11% lower with degludec (P=0.013) [16]. In SWITCH 2 (type 2), nocturnal confirmed hypoglycemia was 36% lower (P<0.001) [17]. These data are directly relevant to Missouri Medicaid prior authorization appeals: documented hypoglycemia on glargine is the clearest clinical path to approval for Tresiba in type 2 diabetes.

Renal and hepatic impairment do not require fixed dose adjustments for Tresiba, though increased monitoring frequency is recommended in severe renal impairment given reduced hypoglycemia counter-regulatory responses [2]. Elderly patients require the same monitoring precautions, with titration proceeding more conservatively, targeting fasting glucose of 100 to 140 mg/dL to reduce fall risk from hypoglycemia per AACE geriatric diabetes guidelines [12].

Drug interactions relevant to Missouri prescribers: thiazolidinediones (pioglitazone) combined with insulin increase fluid retention and heart failure risk; the combination should be used cautiously with documented NYHA class monitoring [2]. GLP-1 receptor agonists added to Tresiba typically allow a 20% basal insulin dose reduction to prevent hypoglycemia, a titration step that reduces monthly drug cost proportionally.

What Happens If You Cannot Afford Tresiba

Several safety-net options exist for Missouri residents who cannot access Tresiba at any of the prices above.

First, NPH insulin remains available over the counter at Walmart pharmacies in Missouri at $25 per vial under the ReliOn brand [4]. NPH is not equivalent to Tresiba pharmacologically (it peaks at 4 to 8 hours and carries higher nocturnal hypoglycemia risk), but it is an option when cost is the sole barrier and the prescriber can adjust the regimen accordingly.

Second, insulin glargine U-300 (Toujeo) and insulin glargine U-100 (Lantus, Basaglar) are on Missouri's Medicaid PDL preferred tier for type 2 diabetes and carry lower list prices than Tresiba. If Medicaid denies Tresiba, one of these alternatives may achieve acceptable glycemic control without an access gap.

Third, the Insulin Help Program run by the nonprofit JDRF connects type 1 patients with emergency insulin supplies. The program ships directly to Missouri residents within 48 hours for qualifying cases [18].

Fourth, 340B-covered federally qualified health centers (FQHCs) in Missouri, including CoxHealth Community Health Centers, Samuel U. Rodgers Health Center in Kansas City, and Grace Hill Health Centers in St. Louis, purchase insulin at deeply discounted 340B prices and pass savings to uninsured patients. A visit to an FQHC can reduce Tresiba's effective cost substantially compared with a retail pharmacy.

A 2023 Health Affairs analysis found that 340B-participating outpatient pharmacies reduced out-of-pocket insulin costs by an average of 68% for low-income uninsured patients compared with retail cash prices [19]. Missouri has 37 FQHC sites participating in 340B as of 2025.